Anthony P. Schwarer

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

David M. Ross, Susan Branford, John F. Seymour et al. · Leukemia · 2010 · 267 citations

Medicine, Molecular Biology, Oncology +15

Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial

C. Orla Morrissey, Sharon C.‐A. Chen, Tania C. Sorrell et al. · The Lancet Infectious Diseases · 2013 · 221 citations

Life Sciences, Infectious Diseases, Microbiology +17

Successful Control of Disseminated Scedosporium prolificans Infection with a Combination of Voriconazole and Terbinafine

Benjamin P. Howden, Monica A. Slavin, Anthony P. Schwarer et al. · European Journal of Clinical Microbiology & Infectious Diseases · 2003 · 198 citations

Life Sciences, Infectious Diseases, Microbiology +6